DPP-4 inhibitors play a unique role in enhancing GLP-1 action by slowing its breakdown, thus prolonging its activity in the body. These inhibitors prevent the rapid degradation of GLP-1, allowing for sustained glucose-lowering effects without the need for frequent doses. By stabilizing endogenous GLP-1 levels, DPP-4 inhibitors improve glycemic control in a natural way. Combined with GLP-1 receptor agonists, they amplify GLP-1’s effects, providing enhanced therapeutic outcomes in blood glucose management, especially for those with type 2 diabetes.
Mehdi, S.F., Pusapati, S., Anwar, M.S., Lohana, D., Kumar, P., Nandula, S.A., Nawaz, F.K., Tracey, K., Yang, H., LeRoith, D., Brownstein, M.J. and Roth, J., 2023. Glucagon-like peptide-1: a multi-faceted anti-inflammatory agent. Frontiers in Immunology
Disclaimer: Information provided it this page is for general information only and does not substitute for professional medical advice.
For detailed information about Semaglutide by Bioamino labs, consult with your doctor or healthcare professional.
Mehdi, S.F., Pusapati, S., Anwar, M.S., Lohana, D., Kumar, P., Nandula, S.A., Nawaz, F.K., Tracey, K., Yang, H., LeRoith, D., Brownstein, M.J. and Roth, J., 2023. Glucagon-like peptide-1: a multi-faceted anti-inflammatory agent. Frontiers in Immunology
Mehdi, S.F., Pusapati, S., Anwar, M.S., Lohana, D., Kumar, P., Nandula, S.A., Nawaz, F.K., Tracey, K., Yang, H., LeRoith, D., Brownstein, M.J. and Roth, J., 2023. Glucagon-like peptide-1: a multi-faceted anti-inflammatory agent. Frontiers in Immunology
Mehdi, S.F., Pusapati, S., Anwar, M.S., Lohana, D., Kumar, P., Nandula, S.A., Nawaz, F.K., Tracey, K., Yang, H., LeRoith, D., Brownstein, M.J. and Roth, J., 2023. Glucagon-like peptide-1: a multi-faceted anti-inflammatory agent. Frontiers in Immunology
Home